Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease
Authors' conclusion
SGLT2 inhibitors were not rarely used in patients with diabetes mellitus who underwent femoropopliteal endovascular therapy using a drug coated balloon for symptomatic peripheral artery disease in real-world settings. SGLT2 inhibitor treatment was not associated with an increased risk of restenosis.
Study context
- Population
- Patients with DM free from end-stage renal disease undergoing femoropopliteal drug-coated balloon endovascular therapy for symptomatic peripheral artery disease, Japan
- Participants
- 1,058 patients
- Exposure
- SGLT2i use vs no SGLT2i
- Outcome
- Prevalence of SGLT2i treatment at revascularization
Methodological detailsmulticenter, propensity score matching
- Multicenter
- Propensity score matching
Main finding
As reported in the abstract
Proportion on SGLT2i at revascularization
14.8%
95% CI 12.8–17.1%
Proportion on SGLT2i in patients with the three associated factors
38.2%
95% CI 25.4–52.3%
Observational data: associations, not effects.
Further findings
| Outcome | SGLT2i | No SGLT2i | P value |
|---|---|---|---|
| Primary patency (freedom from restenosis) · 2 yearsNot different · propensity score-matched analysis | 72.0% (95% CI 64.1–80.9%) | 67.8% (95% CI 62.7–73.3%) | P = 0.45 |
Original publication
Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease. Cardiovasc Diabetol. Published 5 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →